Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter.
Cocrystal Pharma Trading Down 3.8 %
COCP stock opened at $1.53 on Thursday. Cocrystal Pharma has a one year low of $1.35 and a one year high of $3.26. The firm has a market capitalization of $15.57 million, a PE ratio of -0.83 and a beta of 2.35. The firm has a 50-day moving average of $1.89 and a two-hundred day moving average of $1.94.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Cocrystal Pharma in a research note on Wednesday, January 22nd.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- How to Use the MarketBeat Stock Screener
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Using the MarketBeat Dividend Yield Calculator
- Alphabet’s Officially In A Bear Market—Time To Buy?
- What Investors Need to Know About Upcoming IPOs
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
